Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 15548483.
- Also identified by PMC identifier 1738875.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To identify factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin (BTX). 47 patients with writer's cramp were treated with BTX and were evaluated by the same neurologists at initial referral, after each BTX injection, and when the effect of BTX was maximal at the time of the study. Patients and examiners simultaneously and independently rated the efficacy of BTX injections. Self assessment was a global clinical impression of the impact of treatment on writing quality, writing speed, writing errors, and legibility of handwriting; for objective assessment, the examiners used the Burke-Fahn-Marsden (BFM) scale. On the BFM scale, there was a significant improvement (p<0.0001) in both severity and disability scores. Patients with a pronation/flexion pattern of dystonia showed the best and the most sustained improvement. Primary writing tremor was little improved. There was a correlation between the self assessment score and the Burke-Fahn-Marsden score. Benefit was maintained over time These results have implications for the identification of patients most likely to benefit from BTX injections.
Medical subject headings
- Anti-Dyskinesia Agents
- Botulinum Toxins
- Dystonic Disorders